

Chan Hyuk Kim, Ph.D.

• Research Interests

- I. Synthetic immunology and immunotherapy
- II. Therapeutic immune cell engineering
- III. Next-generation antibody engineering

• Education

1997.03 ~ 2003.02: **B.S., Seoul National University, Korea**

Department of Chemistry

2004.03 ~ 2008.08: **Ph.D., Seoul National University, Korea**

Department of Chemistry,

• Professional Career

2021.09~present: **Co-founder**, ILLIMIS Therapeutics Inc.

2017.12 ~ present: **Co-founder**, Curocell Inc.

2021.09 ~ present: **Associate Professor**, Dept. of Biological Sciences, KAIST,

2016.04 ~ 2021.08: **Assistant Professor**, Dept. of Biological Sciences, KAIST, Korea

2012.10 ~ 2016.03: **Principal Investigator**, Dept. of Biology, California institute for Biomedical Research, US

2009.01 ~ 2012.09: **Postdoctoral Associate**, Dept. of Chemistry, The Scripps Research Institute, US

• Honors

Young Investigator Award, The Korean Association of Immunologists, 2017

SRFC Investigator Award, Samsung research Funding & Incubation Center for Future Technology, 2017

Idea Development Award, United States Department of Defense (DoD), 2015

Translation Fund Award, Wellcome-Trust Foundation, 2013

• Selected Recent Publications

1. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Lee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Hupperetz C, Ma JSY, Wang X, Singer O, Kim WS, Kim SJ, Koh Y, Jung I, **Kim CH***. *Mol Ther.* **2021** Oct 8:S1525-0016(21)00498-6. doi: 10.1016/j.ymthe.2021.10.004

2. A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Lee SC, Ma JSY, Kim MS, Laborda E, Choi SH, Hampton EN, Yun H, Nunez V, Muldong MT, Wu CN, Ma W, Kulidjian AA, Kane CJ, Klyushnichenko V, Woods AK, Joseph SB, Petrassi M, Wisler J, Li J, Jamieson CAM, Schultz PG, **Kim CH***, Young TS*. *Sci Adv.* **2021** Aug 11;7(33):eabi8193. doi: 10.1126/sciadv.abi8193

3. Deep-learning-based three-dimensional label-free tracking and analysis of immunological synapses of CAR-T cells. Lee M, Lee YH, Song J, Kim G, Jo Y, Min H, **Kim CH***, Park Y*. *Elife.* **2020** Dec 17;9:e49023. doi: 10.7554/eLife.49023.

4. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, Ma J, Nunez V, Shen J, Woods AK, Wright TM, Schultz PG*, **Kim CH***, Young TS*. *Proc Natl Acad Sci U S A.* **2016** Jan 26;113(4):E459-68.

5. Versatile strategy for controlling the specificity and activity of engineered T cells. Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG*, Young TS*, **Kim CH***, Cao Y. *Proc Natl Acad Sci U S A.* **2016** Jan 26;113(4):E450-8.